Scoop: Stephen Squin­to’s Yale spin­out is rais­ing a Se­ries B for ge­net­ic med­i­cines

The nu­cle­ic acid ther­a­peu­tics at Stephen Squin­to’s Yale-orig­i­nat­ed biotech are en route to a $40 mil­lion R&D pay­day.

Af­ter a Se­ries A of that size in the spring of 2021, Hopewell, NJ-based Gen­nao Bio is clos­ing on a round of the same amount, End­points News has learned. A Se­ries B is in the works, ac­cord­ing to an in­vestor’s post on LinkedIn and as con­firmed by a spokesper­son. An SEC fil­ing on Thurs­day out­lines $15 mil­lion in eq­ui­ty sold thus far in the round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER